University of California, San Francisco
San Francisco, California, 94143, United States
Location status: Recruiting
Location contact
Imani Dunn
CONTACT
Julian Hong, MD, MS
PRINCIPAL_INVESTIGATOR
CONTACT
NCT Number: NCT06587100
This study is being done to collect patient generated health data to predict the risk of patients needing emergency department visits or hospitalization before, during. and after receiving radiation therapy.
Interested in participating?
Request Info18 year and older
All sexes
Observational
San Francisco, California, 94143, United States
Location status: Recruiting
Imani Dunn
CONTACT
Julian Hong, MD, MS
PRINCIPAL_INVESTIGATOR
CONTACT
PRIMARY OBJECTIVE:
I. Validate a previously developed step-count model for predicting all-cause acute care (pooled across all devices).
SECONDARY OBJECTIVES:
I. Validate a previously developed model for predicting each ED visits or hospitalizations during external beam RT using continuous step counts before, during, and after treatment.
II. Validate the previously developed step-count model for predicting all-cause acute care for each of the two different device platforms.
III. Validate concordance of step counts across each of the device's platforms in the Apple group.
IV. Validate the previously developed SHIELD-RT Electronic health record (EHR)-based model for predicting unplanned acute care (ED visit or hospitalization).
EXPLORATORY OBJECTIVES:
I. Refinement of the pre-existing models(step count and SHIELD-RT). II. Evaluate association between wearables collected parameters, EHR-based variables, and acute care events.
III. Develop and validate a multi-modal predictive model for predicting acute care.
OUTLINE: This is an observational study. Participants are assigned to 1 of 2 groups.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Participants will wear Fitbit device
Other names: Wearable Activity Tracker
Participants will wear personal device and share data with study team.
Other names: iPhone, Apple watch
Time frame: Up to 3 years
The AUC-ROC of the step count model will measure the performance of a classification model by plotting the rate of true positives against false positives, and the score ranges from 0 - 1. The higher the AUC, the better the model's performance at distinguishing between the positive and negative classes. The AUC-ROC will be reported including both estimates and confidence intervals. All models will be reported per up-to-date guidelines, such as Minimum Information about Clinical Artificial Intelligence Modeling (MI-CLAIM) and Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD). The performance metrics will only be calculated with respect to first acute care event.
Time frame: Up to 3 years
The Brier Score is a strictly proper score function or strictly proper scoring rule that measures the accuracy of probabilistic predictions. A Brier Score can take on any value between 0 and 1, with 0 being the best score achievable and 1 being the worst score achievable. The lower the Brier Score, the more accurate the prediction(s). The score will be reported including both estimates and confidence intervals. All models will be reported per up-to-date guidelines, such as MI-CLAIM and TRIPOD. The performance metrics will only be calculated with respect to first acute care event.
Time frame: Up to 3 years
Logarithmic loss indicates how close a prediction probability comes to the actual/corresponding true value. The Log-Loss Score can take on any value between 0 and 1. The more the predicted probability diverges from the actual value, the higher is the log-loss value. The log-loss value will be reported including both estimates and confidence intervals. All models will be reported per up-to-date guidelines, such as MI-CLAIM and TRIPOD. The performance metrics will only be calculated with respect to first acute care event.
Time frame: Up to 3 years
The area under the precision-recall curve (AUCPR) is a single number summary of the information in the precision-recall (PR) curve. It represents the tradeoff between precision and recall for different thresholds, where high AUCPR indicates both high recall and high precision. The AUCPR will be reported including both estimates and confidence intervals. All models will be reported per up-to-date guidelines, such as MI-CLAIM and TRIPOD. The performance metrics will only be calculated with respect to first acute care event.
Time frame: Up to 3 years
The AUC-ROC will be used to validate a previously developed model in the primary endpoint for predicting each ED visits or hospitalizations during external beam RT using continuous step counts before, during, and after treatment.
Time frame: Up to 3 years
The AUC-ROC will be used to validate the previously developed step-count model in the primary endpoint for predicting all-cause acute care for each of the two different device platforms.
Time frame: Up to 3 years
The MSE will be used to validate concordance of step counts across each of the device's platforms in the Apple group. Mean Squared Error (MSE) is a fundamental concept in statistics and machine learning in assessing the accuracy of the predictive models which measures the average squared difference between predicted values and the actual values in the dataset.
Time frame: Up to 3 years
Validate the previously developed SHIELD-RT EHR-based model for predicting unplanned acute care (ED visit or hospitalization) to discover additional variables which may be predictors not previously included.
Contact information is provided by the study sponsor or research team.
University of California, San Francisco
Other
Wearable Activity Tracking to Curb Hospitalizations (WATCH)
Acronym: WATCH
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07691008
Hematologic Diseases, Hematologic Neoplasms
View Trial DetailsNCT06881108
Hematologic Diseases, Hematologic Neoplasms
Winston-Salem, North Carolina, United States
View Trial DetailsNCT01437787
Hematologic Diseases, Hematologic Neoplasms
Scottsdale, Arizona, United States
View Trial DetailsNCT01420783
Hematologic Diseases, Hematologic Neoplasms
Scottsdale, Arizona, United States
View Trial Details